P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC

MLA

M. Hernandez, et al. “P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC.” Journal of Thoracic Oncology, vol. 14, Oct. 2019, pp. S676–77. EBSCOhost, https://doi.org/10.1016/j.jtho.2019.08.1435.

APA

M. Hernandez, Elia Neninger, Kirenia Camacho, B. Gonzalez, Y. Menendez, H. Caceres, Eduardo Santiesteban, & C. Del Castillo. (2019). P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC. Journal of Thoracic Oncology, 14, S676–S677. https://doi.org/10.1016/j.jtho.2019.08.1435

Chicago

M. Hernandez, Elia Neninger, Kirenia Camacho, B. Gonzalez, Y. Menendez, H. Caceres, Eduardo Santiesteban, and C. Del Castillo. 2019. “P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC.” Journal of Thoracic Oncology 14 (October): S676–77. doi:10.1016/j.jtho.2019.08.1435.